We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Fluidigm

Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, imm... read more Featured Products: More products

Download Mobile App




Spatial Landscape of Lung Pathology Investigated During COVID-19 Progression

By LabMedica International staff writers
Posted on 13 Apr 2021
Early histopathological changes of viral pneumonias are rarely observed because histopathological examination is not necessary for diagnosis, but late stage changes in viral pneumonias are well defined, most commonly in autopsy series. More...


Since the outbreak of the COVID-19 pandemic, much has been learned regarding its clinical course, prognostic inflammatory markers, disease complications, and mechanical ventilation strategy. Clinically, three stages have been identified based on viral infection, pulmonary involvement with inflammation, and fibrosis.

Medical Scientists at Weill Cornell Medicine (New York, NY, USA) and their colleagues used high parameter imaging mass cytometry to measure the expression level of 36 proteins at single-cell resolution, allowing them to characterize the pathophysiology and immune response in the lungs of 10 patients who died from COVID-19. They investigated at single cell resolution, the cellular composition and spatial architecture of human acute lung injury including SARS-CoV-2. The team also looked at samples from patients who died with acute respiratory distress syndrome from influenza (two patients), bacterial infection (four patients), and bacterial pneumonia (three patients), along with post-mortem lung tissue from four otherwise healthy individuals.

The panel included phenotypic markers of endothelial, epithelial, mesenchymal, and immune cells, functional markers (activation, inflammation and cell death), and an antibody specific to the spike protein of SARS-CoV-2. They used immunohistochemistry and targeted spatial transcriptomic measurements to validate their imaging mass cytometry findings from the Hyperion Imaging System (Fluidigm, South San Francisco, CA, USA).

The scientists reported that the spatially resolved, single-cell data unravels the disordered structure of the infected and injured lung alongside the distribution of extensive immune infiltration. Neutrophil and macrophage infiltration are hallmarks of bacterial pneumonia and COVID-19, respectively. They provided evidence that SARS-CoV-2 infects predominantly alveolar epithelial cells and induces a localized hyper-inflammatory cell state associated with lung damage. They observed increased macrophage extravasation, mesenchymal cells, and fibroblasts abundance concomitant with increased proximity between these cell types as the disease progresses, possibly as an attempt to repair the damaged lung tissue.

Robert Schwartz, MD, PhD, an associate professor of medicine and senior author on the study, said, “In contrast to other lung injury or disease processed, there is widespread tissue damage in late COVID-19 marked by the high amounts of pro-apoptotic cleaved caspase 3 and the off-target deposition of activated complement C5b-C9 attack complex in epithelial cells.”

The authors concluded that this spatial single-cell landscape enabled the pathophysiological characterization of the human lung from its macroscopic presentation to the single-cell, providing an important basis for the understanding of COVID-19, and lung pathology in general. The study was published on March 29, 2021 in the journal Nature.

Related Links:
Weill Cornell Medicine
Fluidigm



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.